For Immediate Release:
May 14, 2021

The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:

  • As part of the FDA’s effort to protect consumers, on April 29, 2021 the agency issued a warning letter to Crown Wellness, Inc. for, among other things, selling an unapproved product with COVID-19 claims. Consumers concerned about COVID-19 should consult with their health care provider.
  • Testing updates:
    • As of today, 372 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 270 molecular tests and sample collection devices, 78 antibody and other immune response tests, and 24 antigen tests. There are 49 molecular authorizations and one antibody authorization that can be used with home-collected samples. There is one molecular prescription at-home test, two antigen prescription at-home tests, four antigen over-the-counter (OTC) at-home tests, and two molecular OTC at-home tests.
    • The FDA has authorized 9 antigen tests and 4 molecular tests for serial screening programs.
      The FDA has also authorized 498 revisions to EUA authorizations.

Related Information

Related Information

###

Boilerplate

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Inquiries

Consumer:
888-INFO-FDA